Objectives: to evaluate cost-effectiveness of continuous erythropoetin receptor activator (MIRCERA) in anemia treatment after 6 months switching to Mircera in continuous ambulatory peritoneal dialysis (CAPD) patients in depatment of Nephrology and Dialysis, ThongNhat Hospital, HCM City.